ImmixBio IMX-110 Supera al Yondelis ... Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin ( Sold as YONDELIS ® by Janssen, a Johnson & Johnson Company ) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study .

IMMX Shares Are Up 57.7% at $2.57 During The Market Session on The Last Check Friday .

 

One cycle of IMX-110 Produced 75% Survival vs. 0% survival for Trabectedin (Sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA Approved Drug) .

Immix Biopharma, Inc.

Fri, May 20, 2022 .

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study . ...